Compare Petróleo Brasileiro SA (PBR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs BIO-TECHNE Corp — how do they compare? Petróleo Brasileiro SA trades at $18.93 (market cap $112.59B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: Petróleo Brasileiro SA is far larger — about 10.1× BIO-TECHNE Corp's market cap, and Petróleo Brasileiro SA pays the higher dividend (9.51%). Which is the better fit depends on your goals.
| PBR | TECH | |
|---|---|---|
Market Cap | $112.59B | $11.16B |
Sector | Technology | Health |
52-Week High | $22.03 | $72.12 |
52-Week Low | $11.54 | $43.31 |
Enterprise Value | $176.05B | $11.24B |
Dividend Yield | 9.51% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $18.19, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a low P/E of 5.73 and robust profitability, including a 21.47% net income margin. Recent news highlights expansion in deepwater operations and strategic partnerships, while earnings have mostly beaten expectations except for a Q1 2026 miss.
The outlook is positive, supported by attractive valuation, solid cash flows, and dividend payments. Risks include oil price volatility and execution of new projects. Analyst consensus leans bullish with 50% buy ratings, but overbought RSI levels suggest near-term caution.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
